GSK Acquires Nuvalent for $10.6B

Summary GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild a leading precision oncology franchise. What Happened Nuvalent has developed…